This is INDEPENDENT, AD-FREE work that you are certainly NOT going to see in conventional media.
Thanks to all who help keep JohnsonAndToxin ad-free, online and me working to expose Johnson & Johnson and their 275+ subsidiaries for the benefit of every man, woman and child on the planet - and that INCLUDES YOU and the ones YOU love.
Stock market analysts claim JNJ growth - um, but it's only an illusion based on corruption, toxic products, harmful devices and fraudulently marketed drugs.
Keywords: jnj, johnson and johnson, johnson + johnson, J&J, toxin, toxic, corruption, lawsuit
Date Created/Edited: 2013, October 24
Pharma: In the pharmacuetical segment of JNJ, they really blew up sales by increasing health risks and costs to consumers with fraudulent marketing, under-payments to health care providers and over-prescribing highly profitable drugs:
Nucynta: J&J painkiller probe expands scrutiny of industry marketing
J&J's Janssen unit gets federal subpoena over opioid painkiller Nucynta
Xarelto: FDA letter to Johnson & Johnson: "The print ad is false or misleading because it minimizes the risks associated with Xarelto and makes a misleading claim."
Medical Devices got a real boost from beginning the replacement of Metal-on-Metal hips around the world. The costs are not being covered by Johnson & Johnson, the costs are pushed through private pay, private insurance, Medicare, Medicaid and the public disability system. Although JNJ's faulty device replacement program is driving up health care costs and destroying economies around the world, it appears as though JNJ is profitting immensely from the distribution and replacement of KNOWN defective products.
Consumer Segment saw a modest increase, even with suspended products and the continued closed facility in Pennsylvania, due to chronic recalls. Recalls are highly profitable because those who purchased $3 to $10 products are more likely to toss them in the trash than return them. The products are then simply replaced creating the illusion of growth.
In the Toxic Products segment, JNJ is still dragging their feet on removing carcinogens and other harmful ingredients from baby care products- continuing to supply a steady supply of victims with cancer, asthma, allergies, eczema, diabetes and neurological disorders to ensure future pharmaceutical sales growth.
In the overall corruption department, JNJ scored again with a pathetic fine, but billions in preferential treatment, in China by violating their anti-monopoly laws. Ahh, corruption to convince people to sell and purchase faulty, inferior devices.
Chinese Court Rendered Final Judgment on Rainbow v. Johnson & Johnson – the First Antitrust Private Action of Vertical Monopolistic Agreement
Well, without corruption, lies, deceit, toxic products, harmful devices and fraudulently marketed drugs, JNJ would barely make any money at all, now would they? Oh, but there'd be far less human suffering - but that wouldn't be good for the stock market, would it?
1. Deborah Weinstein (2013, August 6). J&J painkiller probe expands scrutiny of industry marketing Medical Marketing & Media. Retrieved from http://www.mmm-online.com/jj-painkiller-probe-expands-scrutiny-of-industry-marketing/article/306191/
2. David Sell (2013, August 5). J&J's Janssen unit gets federal subpoena over opioid painkiller Nucynta Philly.com. Retrieved from http://www.philly.com/philly/blogs/phillypharma/JJs-Janssen-unit-gets-federal-subpoena-over-opioid-painkiller-Nucynta.html
3. Zarna Patel, Pharm.D., Amy Toscano, Pharm.D., RAC, CPA (2013, June 6). WARNING LETTER United States Food and Drug Administration. Retrieved from http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/EnforcementActivitiesbyFDA/WarningLettersandNoticeofViolationLetterstoPharmaceuticalCompanies/UCM357833.pdf
4. Emily Patterson (Section page, updated regularly with new content). Twenty Years of KNOWN Carcinogens in J&J US Baby Care Products Finally Ends! Johnson and Toxin. Retrieved from http://www.johnsonandtoxin.com/products.shtml
5. Susan Ning, Liu Jia, Xiao Dasha and Hazel Yin (2013, August 5). Chinese Court Rendered Final Judgment on Rainbow v. Johnson & Johnson – the First Antitrust Private Action of Vertical Monopolistic Agreement China Law Insight. Retrieved from http://www.chinalawinsight.com/2013/08/articles/corporate/antitrust-competition/chinese-court-rendered-final-judgment-on-rainbow-v-johnson-johnson-the-first-antitrust-private-action-of-vertical-monopolistic-agreement/